Caprico Biotechnologies

Stratech

New Product available:
CD105
Stem Cell Research

CD105 (Clone: SN6h; Cat#112515)

Background Information

Mesenchymal stem cells **(MSCs) are recognized as having the greatest potential in stem cell therapy** due to their multi-directional differentiation ability. Different researchers have been using different panel for differential analysis.

Previous studies have shown that MSCs have no specific membrane surface-related antigens, but **mature MSCs can highly express membrane surface markers such as** CD44, CD73, CD90, **CD105**, and do not express CD19, CD11b, CD34, CD45, HLA-DR and other hematopoietic stem cell marker antigens.

The **CD105 antigen** (endoglin) serves as a receptor for the growth and differentiation factors TGF-β1 and TGF-β3, and is expressed on mature endothelial cells, on MSCs with mesodermal differentiation capacity, and on some leukemic cells of B lymphoid and myeloid origin.
The CD105 recognize the same molecular antigen as anti-SH2 antibodies-the most commonly employed antigen for the definition of cultivated MSCs.

CD105 can be used for studies on mesengenesis and for in vitro investigations on hematological disorders. CD105+ bone marrow cells also show multipotent differentiation in vitro and the capacity to form bone in vivo without prior cultivation or differentiation.

CD105 is also expressed on mature endothelial cells and on some leukemic cells of B lymphoid and myeloid origin.

Caprico Biotechnologies

Stratech

Great Performance:



Figure :Live HeLa gated cells stained with CD105 (SN6h) FITC (RED); Live HeLa gated cells are used as FMO control (BLUE).

CBI related products have multi-color conjugations available!
For further information please check our website :

CD73	CD90	CD44	CD45
CD34	CD11b	CD19	SuperLysis buffer

PLEASE CONTACT US FOR ADDITIONAL INFORMATION:

www.stratech.co.uk
+44 (0) 1638 782600
orders@stratech.co.uk
@stratech_uk
@stratechscientificltd
@stratech-scientific-ltd

free delivery for uk universities

we offer a full product guarantee

outstanding technical support

Reference:

1. Dominici M. *et al.* Minimal criteria for defining multipotent mesenchymal stromal cells. *Cryotherapy. 8(4):315-7* (2016).
2. Peter ten Dijke. *et al.* Endoglin in angiogenesis and vascular diseases. *Angiogenesis 11, 79–89 (2008).*
3. Nikolaos A. Dallas. *et al.* Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy. *Clin Cancer Res. (14) (7) 1931-1937 (2008)*

Pub0049 Copyright ©20210120 Caprico Biotechnologies All Rights Reserved